Patent Publication Number: US-2022213174-A1

Title: Ivig treatments for sudden sonsorineural hearing loss

Description:
RELATED APPLICATIONS 
     This application claims priority to U.S. provisional patent application Ser. No. 63/134,144 filed on Jan. 5, 2021. The contents of the aforementioned application are incorporated herein by reference. 
    
    
     FIELD OF THE INVENTION 
     The subject of this patent application relates generally to treatments for Hearing Loss, and more particularly to Intravenous immunoglobulin (IVIG) treatments for Hearing Loss. 
     BACKGROUND 
     Hearing Loss can occur due to several factors, including an infection, physical trauma (including head trauma), Meniere&#39;s diseases, side effect of certain drugs or medications, circulation problems, the natural aging process, conductive deafness, loud noises, nerve damage or a genetic disorder. There are multiple types of Hearing Loss, but a common type of Hearing Loss is Sudden Sensorineural Hearing Loss. Sudden Sensorineural Hearing Loss can occur when hair cells (stereocilia in the cochlea) in the inner ear are damaged or there is damage to the auditory nerve. Sudden Sensorineural Neural Hearing Loss can last for several years or in some instances, it can be lifelong. Sudden Sensorineural Neural Hearing Loss can range from mild hearing loss to complete hearing loss depending on the damage to the stereocilia in one ear or in both ears. 
     Among the side effects of Sudden Sensorineural Neural Hearing Loss include: trouble hearing sounds when there is background noise, dizziness, balance problems, trouble hearing high-pitched sounds, sounds and voices seem muffled, feeling like you can hear voices but cannot understand them and tinnitus. The different types of Sensorineural Neural Hearing Loss include Bilateral Sensorineural Neural Hearing Loss, Unilateral Sensorineural Neural Hearing Loss and Asymetrical Sensorineural Neural Hearing Loss. 
     Sensorineural Neural Hearing Loss can be determined through a physical exam, tuning forks (the Weber&#39;s Test or the Rinne Test) or an audiogram. Currently, treatments for Sensorineural Neural Hearing Loss include the use of hearing aids and cochlear implants. 
     A form of Sensorineural Neural Hearing Loss is Sudden Sensorineural Neural Hearing Loss which occurs in about 5-20 in 100,000 people and usually only affects one ear. It is generally noticed after waking in the morning. Sudden Sensorineural Neural Hearing Loss leads to deafness either instantly or over a few days. The most common treatment option for Sudden Sensorineural Neural Hearing Loss is the prescription of corticosteroids, which work best when provided within two weeks of the onset of Sudden Sensorineural Neural Hearing Loss. The outlook for individuals who suffer from Sudden Sensorineural Neural Hearing Loss is highly variable and depends on the extent and cause of hearing loss. In the case of Sudden Sensorineural Neural Hearing Loss about 85% of individuals experience at least a partial recovery if they receive treatment. 
     Intravenous immunoglobulin (IVIG) is a blood product prepared from the serum of one or more donors. IVIG is used as an ‘immunomodulatory’ agent in an increasing number of immune and inflammatory disorders. Furthermore, IVIG is used to treat hematology related disorders, such as immune cytopenias, parvovirus B19 associated red cell aplasia, hypogammaglobulinaemia secondary to myeloma and chronic lymphatic leukaemia and post-bone marrow transplantation. In the field of immunology, IVIG is used in the treatment of primary antibody deficiency (PAD). In the field of nephrology, IVIG is used in the treatment of rheumatology. Additional new treatments employing IVIG are needed. 
     Applicant submits that more effective therapeutic treatments for Hearing Loss patients, including Sensorineural Neural Hearing Loss (and Sudden Sensorineural Neural Hearing Loss) are needed. In this aspect, IVIG has been disclosed herein as an improved treatment for Hearing Loss including Sensorineural Neural Hearing Loss (and Sudden Sensorineural Neural Hearing Loss) and associated symptoms. 
     Applicant hereby incorporate herein by reference any and all patents and published patent applications cited or referred to in this application. Aspects of the present disclosure fulfill these needs and provide further related advantages as described in the following summary. 
     SUMMARY 
     Aspects of the present disclosure teach certain benefits in construction and use which give rise to the exemplary advantages described below. 
     In one aspect, the present disclosure solves the problems described above by providing a method for treating Hearing Loss disease in a subject in need thereof, the method comprising: administering a therapeutically effective amount of a composition comprising human intravenous immunoglobulin (IVIG) to a subject. 
     In another aspect, the Hearing Loss to treat is Sudden Sensorineural Hearing Loss or Sudden Sensorineural Hearing Loss. 
     Another aspect is a method for treating Sudden Sensorineural Hearing Loss disease in a subject in need thereof that includes co-administering a steroid with human intravenous immunoglobulin (IVIG). 
     The steroid can be one that is known in the art, including prednisolone, valaciclovir, cortisone acetate, methylprednisolone, corticotropin. In one aspect, immunoglobulin is co-administered with prednisone or methylprednisone administered in an amount between about 5 mg/day to 200 mg/day. In one aspect, the immunoglobulin is administered in an amount between about 0.1 g/kg to 10 g/kg of the subject. The immunoglobulin can be administered in one or more doses during a two-week to eight-week period. 
     In another aspect, the immunoglobulin is administered at an amount between about 0.1 g/kg to 10 g/kg of the subject administered over between about a two-week to eight-week period, wherein the amount is administered in one or more doses during the two-week to eight-week period. Alternatively, the immunoglobulin is administered at an amount between about 2 g/kg to 7 g/kg of the subject, wherein the amount is administered in one or more doses during a three-week to six-week period. In yet another aspect, the immunoglobulin is administered at an amount between about 2 g/kg to 7 g/kg of the subject, wherein the immunoglobulin is administered in one dose. 
     The steroid (e.g. prednisone or methylprednisone) can be administered in an amount between about 20 mg/day to 100 mg/day. In another aspect, the steroid is administered in an amount of about 60 mg/day. 
     In one aspect, Sudden Sensorineural Hearing Loss is 50-70% resolved within two weeks. In another aspect, Sudden Sensorineural Hearing Loss is completely resolved within two weeks. 
     In one aspect, Sudden Sensorineural Hearing Loss symptoms are 50-70% reduced within two weeks. In another aspect, Sudden Sensorineural Hearing Loss symptoms are completely resolved within two weeks. 
     Another aspect is a method for treating Sudden Sensorineural Hearing Loss disease that includes administering a therapeutically effective amount of a composition comprising human intravenous immunoglobulin (IVIG) and a steroid to a subject. The steroid can be prednisone that is administered to the subject at a dose of 60 mg. The IVIG can be administered to the subject at a dose of 2 g/kg body weight. 
     Other features and advantages of aspects of the present disclosure will become apparent from the following more detailed description. 
    
    
     DETAILED DESCRIPTION 
     In one aspect, the present disclosure solves the problems described above by providing a method for treating Hearing Loss disease in a subject in need thereof, the method comprising: administering a therapeutically effective amount of a composition comprising human intravenous immunoglobulin (IVIG) to a subject. 
     In another aspect, the present disclosure solves the problems described above by providing a method for treating Hearing Loss disease in a subject in need thereof, the method comprising: administering a therapeutically effective amount of a composition comprising human intravenous immunoglobulin (IVIG) to a subject, and wherein the immunoglobulin is administered with a steroid. 
     Hearing Loss is generally caused by several factors, including an infection, physical trauma (including head trauma), Meniere&#39;s diseases, side effect of certain drugs or medications, circulation problems, the natural aging process, conductive deafness, loud noises, nerve damage or a genetic disorder. There are multiple types of Hearing Loss, but one of the types is Sudden Sensorineural Hearing Loss that can occur when hair cells (stereocilia in the cochlea) in the inner ear are damaged or there is damage to the auditory nerve. Sudden Sensorineural Neural Hearing Loss can last for several years or in some instances, it can be lifelong. Sudden Sensorineural Neural Hearing Loss can occur in one ear or in both ears. 
     Diagnosis can be conducted through a physical exam, the use of tuning forks or an audiogram. With regard to a physical exam, this is based on a subject&#39;s physical exam wherein the doctor searches for inflammation, fluid or earwax buildup, damage to the eardrum and foreign bodies. A doctor using a tuning fork test as an initial screening can use the Weber&#39;s test. This test involves the doctor striking a 512 Hz tuning fork softly and places it near the midline of the patient&#39;s forehead. Another test using a tuning fork is the Rinne Test. This test involves the doctor striking a tuning fork and placing it against the mastoid bone behind the ear of a patient, leaving it there until the patient can no longer hear the sound. The next part of the Rinne Test is the tuning fork is moved in front of the ear canal until the patient can no longer hear a sound. If a patient has Sudden Sensorineural Neural Hearing Loss, the patient will hear the tuning fork in front of the ear canal better than against the mastoid bone. 
     Once a patient is suspected of having Sudden Sensorineural Neural Hearing Loss, the patient is generally sent for a more accurate audiometer test. 
     Current treatments for Sudden Sensorineural Neural Hearing Loss include the use of corticosteroids, hearing aids and cochlear implants. There is currently no surgical option to treat Sudden Sensorineural Neural Hearing Loss. 
     It is postulated that inflammation of the auditory nerve can block the transmission of neural signals and/or damaging the nerve causing Sudden Sensorineural Neural Hearing Loss. 
     The disclosure herein relates to treating Hearing Loss patients, including Sudden Sensorineural Neural Hearing Loss with intravenous immunoglobulin (IVIG) with or without corticosteroids, whereby the patient&#39;s Hearing Loss, including Sudden Sensorineural Neural Hearing Loss is resolved in less time than with corticosteroids alone or in combination with antivirals. In an embodiment, IVIG can be comprised of polyclonal antibodies, a monoclonal antibody, a mixture of different monoclonal antibodies, a mixture of polyclonal antibodies and a monoclonal antibody and/or polyclonal antibodies and a mixture of different monoclonal antibodies. 
     IVIG is recognized as a safe therapy without the side effects of steroids or other immunosuppressive agents. There have been numerous recent advances in our understanding of the mechanisms of action of IVIG and has been used in the fields of neurology, haematology, immunology, rheumatology, and dermatology. 
     Side effects of IVIG therapy are managed in some cases with premedication with analgesics and antihistamines and adjustment of the infusion rate. Therefore, as disclosed herein It will be important with IVIG to employ a minimum number of low doses to the patient, while providing rapid recovery from Hearing Loss, including Sudden Sensorineural Neural Hearing Loss. 
     National bodies and medical associations have established varying standards for the use of immunoglobulin therapy to treat a disease. 
     Side effects of immunoglobulin infusions can include itching, rash, and hives. Moreover, more severe systemic side effects to immunoglobulin infusions can include an increased heart rate, hyper or hypotension, an increased body temperature, diarrhea, nausea, abdominal pain, vomiting, arthralgia or myalgia, dizziness, headache, fatigue, fever, and/or pain. Serious side effects of immunoglobulin infusions can include chest pain, myocardial infarction, tachycardia hyponatremia, hemolysis, hemolytic anemia, thrombosis, hepatitis, anaphylaxis, backache, aseptic meningitis, acute renal failure, hypokalemic nephropathy, pulmonary embolism, and transfusion related lung injury. 
     In order to avert less serious side effects, the patient&#39;s infusion rate can be adjusted lower to reduce or eliminate the side effects. 
     Commercial names of intravenous immunoglobulin formulations include Flebogamma®, Gamunex®, Privigen™, Octagam® and Gammagard®, HyQvia™, Hizentra™ (CSL Behring), Gamunex-C™, and Gammaked™. 
     Administration of the immunoglobulin formulations disclosed herein to a subject may be intravenous and/or subcutaneous. In some embodiments, the immunoglobulin is administered with a steroid. In some embodiments, the immunoglobulin is co-administered with a steroid, wherein the steroid is prednisone or methylprednisone. In some embodiments, the immunoglobulin is co-administered with a steroid, wherein the steroid is prednisone administered in an amount between about 5 mg/day to 200 mg/day. In some embodiments, the IVIG is co-administered with a steroid, such as a cortical steroid and further, wherein an embodiment the steroid is prednisone, and wherein the prednisone is administered in an amount of, e.g. at least 10 mg/day, at least 20 mg/day, at least 30 mg/day, at least 40 mg/day, at least 50 mg/day, at least 60 mg/day, at least 70 mg/day, at least 80 mg/day, at least 90 mg/day, at least 100 mg/day, at least 110 mg/day, at least 120 mg/day, at least 130 mg/day, at least 140 mg/day, at least 150 mg/day, at least 160 mg/day, at least 170 mg/day, at least 180 mg/day, at least 190 mg/day, at least 200 mg/day, at least 210 mg/day, at least 220 mg/day, at least 230 mg/day, at least 240 mg/day, at least 250 mg/day, at least 260 mg/day, at least 270 mg/day, at least 280 mg/day, at least 290 mg/day, at least 300 mg/day, at least 310 mg/day, at least 320 mg/day, at least 330 mg/day, at least 340 mg/day, at least 350 mg/day, at least 360 mg/day, at least 370 mg/day, at least 380 mg/day, at least 390 mg/day, at least 400 mg/day, at least 410 mg/day, at least 420 mg/day, at least 430 mg/day, at least 440 mg/day, at least 450 mg/day, at least 460 mg/day, at least 470 mg/day, at least 480 mg/day, at least 490 mg/day, at least 500 mg/day, at least 510 mg/day, at least 520 mg/day, at least 530 mg/day, at least 540 mg/day, at least 550 mg/day, at least 600 mg/day, at least 650 mg/day, at least 700 mg/day, at least 750 mg/day, or at least 800 mg/day and wherein the IVIG is administered in an amount of at least 0.01 g/day, at least 0.05 g/day, at least 0.1 g/day, at least 0.5 g/day, at least 1 g/day, at least 2 g/day, at least 3 g/day, at least 4 g/day, at least 5 g/day, at least 6 g/day, at least 7 g/day, at least 8 g/day, at least 9 g/day, at least 10 g/day, at least 20 g/day, at least 30 g/day, at least 40 g/day, at least 50 g/day, at least 60 g/day, at least 70 g/day, at least 80 g/day, at least 90 g/day, at least 100 g/day, at least 110 g/day, at least 120 g/day, at least 130 g/day, at least 140 g/day, at least 150 g/day, at least 160 g/day, at least 170 g/day, at least 180 g/day, at least 190 g/day, at least 200 g/day, at least 210 g/day, at least 220 g/day, at least 230 g/day, at least 240 g/day, at least 250 g/day, at least 260 g/day, at least 270 g/day, at least 280 g/day, at least 290 g/day, at least 300 g/day, at least 310 g/day, at least 320 g/day, at least 330 g/day, at least 340 g/day, at least 350 g/day, at least 360 g/day, at least 370 g/day, at least 380 g/day, at least 390 g/day, at least 400 g/day, at least 410 g/day, at least 420 g/day, at least 430 g/day, at least 440 g/day, at least 450 g/day, at least 460 g/day, at least 470 g/day, at least 480 g/day, at least 490 g/day, at least 500 g/day, at least 510 g/day, at least 520 g/day, at least 530 g/day, at least 540 g/day, at least 5550 g/day, at least 600 g/day, at least 650 g/day, at least 700 g/day, at least 750 g/day, or at least 800 g/day. 
     In some embodiments, the IVIG is administered separately from a steroid, wherein the steroid is prednisone or methylprednisone. In some embodiments, the IVIG is administered separately from a steroid, wherein the steroid is prednisone or methylprednisone administered in an amount between, e.g. about 5 mg/day to 200 mg/day. In some embodiments, the IVIG is administered separately from a steroid, wherein the steroid is prednisone or methylprednisone which in an embodiment is administered in an amount of at least 1 g/day, at least 10 g/day, at least 20 g/day, at least 30 g/day, at least 40 g/day, at least 50 g/day, at least 60 g/day, at least 70 g/day, at least 80 g/day, at least 90 g/day, at least 100 g/day, at least 110 g/day, at least 120 g/day, at least 130 g/day, at least 140 g/day, at least 150 g/day, at least 160 g/day, at least 170 g/day, at least 180 g/day, at least 190 g/day, at least 200 g/day, at least 210 g/day, at least 220 g/day, at least 230 g/day, at least 240 g/day, at least 250 g/day, at least 260 g/day, at least 270 g/day, at least 280 g/day, at least 290 g/day, at least 300 g/day, at least 310 g/day, at least 320 g/day, at least 330 g/day, at least 340 g/day, at least 350 g/day, at least 360 g/day, at least 370 g/day, at least 380 g/day, at least 390 g/day, at least 400 g/day, at least 410 g/day, at least 420 g/day, at least 430 g/day, at least 440 g/day, at least 450 g/day, at least 460 g/day, at least 470 g/day, at least 480 g/day, at least 490 g/day, at least 500 g/day, at least 510 g/day, at least 520 g/day, at least 530 g/day, at least 540 g/day, at least 5550 g/day, at least 600 g/day, at least 650 g/day, at least 700 g/day, at least 750 g/day, or at least 800 g/day; and wherein the prednisone is administered in an amount of at least 0.1 mg, at least 0.5 mg, at least 1 mg, at least 1.5 mg, at least 2 mg, at least 2.5 mg, at least 3 mg, at least 3.5 mg, at least 4 mg, at least 4.5 mg, at least 5 mg, at least 5.5 mg, at least 6 mg, at least 6.5 mg, at least 7 mg, at least 7.5 mg, at least 8 mg, at least 8.5 mg, at least 9 mg, at least 9.5 mg, at least 10 mg, at least 11 mg, at least 12 mg, at least 13 mg, at least 14 mg, at least 15 mg, at least 16 mg, at least 17 mg, at least 18 mg, at least 19 mg, at least 20 mg, at least 21 mg, at least 22 mg, at least 23 mg, at least 24 mg, at least 25 mg, at least 26 mg, at least 27 mg, at least 28 mg, at least 29 mg, at least 30 mg, at least 31 mg, at least 32 mg, at least 33 mg, at least 34 mg, at least 35 mg, at least 36 mg, at least 37 mg, at least 38 mg, at least 39 mg, at least 40 mg, at least 41 mg, at least 42 mg, at least 43 mg, at least 44 mg, at least 45 mg, at least 46 mg, at least 47 mg, at least 48 mg, at least 49 mg, at least 50 mg, at least 51 mg, at least 52 mg, at least 53 mg, at least 54 mg, at least 55 mg, at least 56 mg, at least 57 mg, at least 58 mg, at least 59 mg, at least 60 mg, at least 61 mg, at least 62 mg, at least 63 mg, at least 64 mg, at least 65 mg, at least 66 mg, at least 67 mg, at least 68 mg, at least 69 mg, at least 70 mg, at least 71 mg, at least 72 mg, at least 73 mg, at least 74 mg, at least mg, at least 76 mg, at least 77 mg, at least 78 mg, at least 79 mg, at least 80 mg, at least 81 mg, at least 82 mg, at least 83 mg, at least 84 mg, at least 85 mg, at least 86 mg, at least 87 mg, at least 88 mg, at least 89 mg, at least 90 mg, at least 91 mg, at least 92 mg, at least 93 mg, at least 94 mg, at least 95 mg, at least 96 mg, at least 97 mg, at least 98 mg, at least 99 mg, at least 100 mg, mg, at least 125 mg, at least 150 mg, at least 175 mg, at least 200 mg, at least 225 mg, at least 250 mg, at least 275 mg, at least 300 mg, at least 325 mg, at least 350 mg, at least 375 mg, at least 400 mg, at least 425 mg, at least 450 mg, at least 475 mg, or at least 500 mg. In some embodiments, the therapeutically effective amount of IVIG is between about at least 1 g/day, at least 10 g/day, at least 20 g/day, at least 30 g/day, at least 40 g/day, at least 50 g/day, at least 60 g/day, at least 70 g/day, at least 80 g/day, at least 90 g/day, at least 100 g/day, at least 110 g/day, at least 120 g/day, at least 130 g/day, at least 140 g/day, at least 150 g/day, at least 160 g/day, at least 170 g/day, at least 180 g/day, at least 190 g/day, at least 200 g/day, at least 210 g/day, at least 220 g/day, at least 230 g/day, at least 240 g/day, at least 250 g/day, at least 260 g/day, at least 270 g/day, at least 280 g/day, at least 290 g/day, at least 300 g/day, at least 310 g/day, at least 320 g/day, at least 330 g/day, at least 340 g/day, at least 350 g/day, at least 360 g/day, at least 370 g/day, at least 380 g/day, at least 390 g/day, at least 400 g/day, at least 410 g/day, at least 420 g/day, at least 430 g/day, at least 440 g/day, at least 450 g/day, at least 460 g/day, at least 470 g/day, at least 480 g/day, at least 490 g/day, at least 500 g/day, at least 510 g/day, at least 520 g/day, at least 530 g/day, at least 540 g/day, at least 5550 g/day, at least 600 g/day, at least 650 g/day, at least 700 g/day, at least 750 g/day, or at least 800 g/day. 
     In some embodiments, the therapeutically effective amount of IVIG is between about 0.1 g/kg to 10 g/kg of the subject, wherein the amount is administered in one or more doses during a two-week to eight-week period. In some embodiments, the therapeutically effective amount of IVIG is between about 0.1 g/kg to 10 g/kg of the subject administered over between about a two-week to eight-week period, wherein the amount is administered in one or more doses during the two-week to eight-week period. In some embodiments, the therapeutically effective amount of IVIG is between about 0.5 g/kg to 7 g/kg of the subject, wherein the amount is administered in one or more doses during a three-week to six-week period. In some embodiments, the therapeutically effective amount of IVIG is between about 0.5 g/kg to 7 g/kg of the subject, wherein the IVIG is administered in one dose. In some embodiments, the therapeutically effective amount of IVIG is between about 0.5 g/kg to 7 g/kg of the subject, wherein the immunoglobulin is administered in one dose, and wherein prednisone is administered in an amount between about 20 mg/day to 100 mg/day. In some embodiments, the therapeutically effective amount of IVIG is about 2 g/kg of the subject, wherein the immunoglobulin is administered in one dose, and wherein prednisone is administered in an amount of about 60 mg/day. In some embodiments, the composition is dispersed in a pharmaceutically acceptable solution. 
     Treatment during the acute phase of Hearing Loss, including Sudden Sensorineural Healing Loss, includes strategies to reduce recovery time and to prevent corneal complications. Current strategies to speed recovery include hearing aids, cochlear implants and corticosteroids. 
     The rationale for the use of corticosteroids during Hearing Loss, including Sudden Sensorineural Healing Loss, is that inflammation of the auditory nerve can result Hearing Loss and corticosteroid&#39;s anti-inflammatory effects minimize nerve damage and thereby improve the outcome. 
     Randomized, double-blind, placebo-controlled trials have provided compelling evidence that treatment with prednisolone or methylprednisone improves outcome in patients with Hearing Loss, including Sudden Sensorineural Healing Loss, and shortens the time to complete recovery. Prednisolone or methylprednisone should be used in all patients with Hearing Loss, including Sudden Sensorineural Healing Loss, of less than two weeks duration who do not have contraindications to steroid therapy. The prednisolone dose used was 60 mg per day for 5 days then reduced by 10 mg per day and 50 mg per day for 10 days. In some embodiments, Hearing Loss, including Sudden Sensorineural Healing Loss, is 50-70% resolved within two weeks. In some embodiments, Hearing Loss, including Sudden Sensorineural Healing Loss, is completely resolved within two weeks. In some embodiments, Hearing Loss, including Sudden Sensorineural Healing Loss, symptoms are 50-70% reduced within two weeks. In some embodiments, Hearing Loss, including Sudden Sensorineural Healing Loss symptoms are completely resolved within two weeks. 
     In other aspects of this embodiment, administration of IVIG with or without corticosteroids as disclosed herein reduces the severity of Hearing Loss, including Sudden Sensorineural Healing Loss by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95%. In yet other aspects of this embodiment, administration of IVIG with or without corticosteroids as disclosed herein reduces the severity of Hearing Loss, including Sudden Sensorineural Healing Loss from, e.g., about 5% to about 100%, about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70%. 
     A pharmaceutical composition disclosed herein comprising IVIG with or without a cortical steroid is administered in an amount sufficient to allow customary administration to an individual. In aspects of this embodiment, the IVIG disclosed herein may be administered at a dose of, e.g., at least 10 g, at least 20 g, at least 30 g, at least 40 g, at least 50 g, at least 60 g, at least 70 g, at least 80 g, at least 90 g, at least 100 m, at least 110 g, at least 120 g, at least 130 g, at least 140 g, at least 150 g, at least 160 g, at least 170 g, at least 180 g, at least 190 g, at least 200 .g, at least 210 g, at least 220 g, at least 230 g, at least 240 g, at least 250 g, at least 260 g, at least 270 g, or at least 280 g of IVIG. In other aspects of this embodiment, an IVIG with or without a cortical steroid as disclosed herein may be, e.g., at least 10 g, at least 20 g, at least 30 g, at least 40 g, at least 50 mg, at least 60 g, at least 70 g, at least 80 g, at least 90 g, at least 100 m, at least 110 g, at least 120 g, at least 130 g, at least 140 g, at least 150 g, at least 160 g, at least 170 g, at least 180 g, at least 190 g, at least 200 .g, at least 210 g, at least 220 g, at least 230 g, at least 240 g, at least 250 g, at least 260 g, at least 270 g, or at least 280 g of IVIG. In yet other aspects of this embodiment, IVIG with or without a cortical steroid as disclosed herein may be in the range of, e.g., about 10 g to about 280 g, about 50 g to about 250 g, about 75 g to about 225 g, about 100 g to about 200 g, about 75 g to about 200 g, about 50 g to about 225 g, about 100 g to about 250 g, about 80 g to about 225 g, about 80 g to about 200 g, about 90 g to about 250 g, about 90 g to about 225 g, or about 90 g to about 200 g. 
     IVIG with or without a cortical steroid as disclosed herein may comprise a solvent, emulsion or other diluent in an amount sufficient to dissolve IVIG with or without a cortical steroid as disclosed herein. In other aspects of this embodiment, IVIG with or without a cortical steroid as disclosed herein may comprise a solvent, emulsion or a diluent in an amount of, e.g., less than about 90% (v/v), less than about 80% (v/v), less than about 70% (v/v), less than about 65% (v/v), less than about 60% (v/v), less than about 55% (v/v), less than about 50% (v/v), less than about 45% (v/v), less than about 40% (v/v), less than about 35% (v/v), less than about 30% (v/v), less than about 25% (v/v), less than about 20% (v/v), less than about 15% (v/v), less than about 10% (v/v), less than about 5% (v/v), or less than about 1% (v/v). In other aspects of this embodiment, IVIG with or without a cortical steroid as disclosed herein may comprise a solvent, emulsion or other diluent in an amount in a range of, e.g., about 1% (v/v) to 90% (v/v), about 1% (v/v) to 70% (v/v), about 1% (v/v) to 60% (v/v), about 1% (v/v) to 50% (v/v), about 1% (v/v) to 40% (v/v), about 1% (v/v) to 30% (v/v), about 1% (v/v) to 20% (v/v), about 1% (v/v) to 10% (v/v), about 2% (v/v) to 50% (v/v), about 2% (v/v) to 40% (v/v), about 2% (v/v) to 30% (v/v), about 2% (v/v) to 20% (v/v), about 2% (v/v) to 10% (v/v), about 4% (v/v) to 50% (v/v), about 4% (v/v) to 40% (v/v), about 4% (v/v) to 30% (v/v), about 4% (v/v) to 20% (v/v), about 4% (v/v) to 10% (v/v), about 6% (v/v) to 50% (v/v), about 6% (v/v) to 40% (v/v), about 6% (v/v) to 30% (v/v), about 6% (v/v) to 20% (v/v), about 6% (v/v) to 10% (v/v), about 8% (v/v) to 50% (v/v), about 8% (v/v) to 40% (v/v), about 8% (v/v) to 30% (v/v), about 8% (v/v) to 20% (v/v), about 8% (v/v) to 15% (v/v), or about 8% (v/v) to 12% (v/v). 
     The final concentration of IVIG with or without a cortical steroid as disclosed herein may be of any concentration desired. In an aspect of this embodiment, the final concentration of IVIG with or without a cortical steroid in a pharmaceutical composition may be a therapeutically effective amount. In other aspects of this embodiment, the final concentration of IVIG with or without a cortical steroid in a pharmaceutical composition may be, e.g., at least 0.01 g/mL, at least 0.02 g/mL, at least 0.03 g/mL, at least 0.04 g/mL, at least 0.05 g/mL, at least 0.06 g/mL, at least 0.07 g/mL, at least 0.08 g/mL, at least 0.09 g/mL, at least 0.1 g/mL, at least 0.2 g/mL, at least 0.3 g/mL, at least 0.4 g/mL, at least 0.5 g/mL, at least 0.6 g/mL, at least 0.7 g/mL, at least 0.8 g/mL, at least 0.9 g/mL, at least 1 g/mL, at least 1.25 g/mL, g/mL, at least 1.5 g/mL, at least 1.75 g/mL, at least 2 g/mL, at least 2.25 g/mL, at least 2.5 g/mL, at least 2.75 g/mL, at least 3 g/mL, 3.25 g/mL, at least 3.5 g/mL, at least 3,75 g/mL, at least 4 g/mL, 4.25 g/mL, at least 4.5 g/mL, at least 4.75 g/mL, at least 5 g/mL, 5.25 g/mL, at least 5.5 g/mL, at least 5.75 g/mL, at least 6g/mL, 6.25 g/mL, at least 6.5 g/mL, at least 6.75 g/mL, at least 7 g/mL, 7.25 g/mL, at least 7.5 g/mL, at least 7.75 g/mL, at least 8 g/mL, 8.25 g/mL, at least 8.5 g/mL, at least 8.75 g/mL, at least 9 g/mL, 9.25 g/mL, at least 9.5 g/mL, at least 9.75 g/mL, at least 10 g/mL. In other aspects of this embodiment, the concentration of IVIG with or without a cortical steroid as disclosed herein in the solution may be, e.g., at most 0.01 g/mL, at most 0.02 g/mL, at most 0.03 g/mL, at most 0.04 g/mL, at most 0.05 g/mL, at most 0.06 g/mL, at most 0.07 g/mL, at most 0.08 g/mL, at most 0.09 g/mL, at most 0.1 g/mL, at most 0.2 g/mL, at most 0.3 g/mL, at most 0.4 g/mL, at most 0.5 g/mL, at most 0.6 g/mL, at most 0.7 g/mL, at most 0.8 g/mL, at most 0.9 g/mL, at most 1 g/mL, at most 1.25 g/mL, g/mL, at most 1.5 g/mL, at most 1.75 g/mL, at most 2 g/mL, at most 2.25 g/mL, at most 2.5 g/mL, at most 2.75 g/mL, at most 3 g/mL, 3.25 g/mL, at most 3.5 g/mL, at most 3,75 g/mL, at most 4 g/mL, 4.25 g/mL, at most 4.5 g/mL, at most 4.75 g/mL, at most 5 g/mL, 5.25 g/mL, at most 5.5 g/mL, at most 5.75 g/mL, at most 6g/mL, 6.25 g/mL, at most 6.5 g/mL, at most 6.75 g/mL, at most 7 g/mL, 7.25 g/mL, at most 7.5 g/mL, at most 7.75 g/mL, at most 8 g/mL, 8.25 g/mL, at most 8.5 g/mL, at most 8.75 g/mL, at most 9 g/mL, 9.25 g/mL, at most 9.5 g/mL, at most 9.75 g/mL, at most 10 g/mL. In other aspects of this embodiment, the final concentration of IVIG with or without a cortical steroid in a pharmaceutical composition may be in a range of, e.g., about 0.01 g/mL, about 0.02 g/mL, about 0.03 g/mL, about 0.04 g/mL, about 0.05 g/mL, about 0.06 g/mL, about 0.07 g/mL, about 0.08 g/mL, about 0.09 g/mL, about 0.1 g/mL, about 0.2 g/mL, about 0.3 g/mL, about 0.4 g/mL, about 0.5 g/mL, about 0.6 g/mL, about 0.7 g/mL, about 0.8 g/mL, about 0.9 g/mL, about 1 g/mL, about 1.25 g/mL, g/mL, about 1.5 g/mL, about 1.75 g/mL, about 2 g/mL, about 2.25 g/mL, about 2.5 g/mL, about 2.75 g/mL, about 3 g/mL, 3.25 g/mL, about 3.5 g/mL, about 3,75 g/mL, about 4 g/mL, 4.25 g/mL, about 4.5 g/mL, about 4.75 g/mL, about 5 g/mL, 5.25 g/mL, about 5.5 g/mL, about 5.75 g/mL, about 6g/mL, 6.25 g/mL, about 6.5 g/mL, about 6.75 g/mL, about 7 g/mL, 7.25 g/mL, about 7.5 g/mL, about 7.75 g/mL, about 8 g/mL, 8.25 g/mL, about 8.5 g/mL, about 8.75 g/mL, about 9 g/mL, 9.25 g/mL, about 9.5 g/mL, about 9.75 g/mL, about 10 g/mL. 
     Aspects of the present specification disclose, in part, treating an individual suffering from Hearing Loss, including Sudden Sensorineural Healing Loss. As used herein, the term “treating,” refers to reducing or eliminating in an individual a clinical symptom of Hearing Loss, including Sudden Sensorineural Healing Loss; or delaying or preventing in an individual the onset of a clinical symptom of Hearing Loss, including Sudden Sensorineural Healing Loss. For example, the term “treating” can mean reducing a symptom of a condition characterized by Hearing Loss, including Sudden Sensorineural Healing Loss, including, but not limited to, a reduction of, e.g., at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% at least 95%, or at least 100%. Those of skill in the art will know the appropriate symptoms or indicators associated with a Hearing Loss, including Sudden Sensorineural Healing Loss and will know how to determine if an individual is a candidate for treatment as disclosed herein. 
     In aspects of this embodiment, a therapeutically effective amount of IVIG with or without a cortical steroid as disclosed herein reduces a symptom associated with Hearing Loss, including Sudden Sensorineural Healing Loss by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 100%. In other aspects of this embodiment, a therapeutically effective amount of IVIG with or without a cortical steroid as disclosed herein reduces a symptom associated with Hearing Loss, including Sudden Sensorineural Healing Loss by, e.g., at most 10%, at most 15%, at most 20%, at most 25%, at most 30%, at most 35%, at most 40%, at most 45%, at most 50%, at most 55%, at most 60%, at most 65%, at most 70%, at most 75%, at most 80%, at most 85%, at most 90%, at most 95% or at most 100%. In yet other aspects of this embodiment, a therapeutically effective amount of IVIG with or without a cortical steroid as disclosed herein reduces a symptom associated with Hearing Loss, including Sudden Sensorineural Healing Loss by, e.g., about 10% to about 100%, about 10% to about 90%, about 10% to about 80%, about 10% to about 70%, about 10% to about 60%, about 10% to about 50%, about 10% to about 40%, about 20% to about 100%, about 20% to about 90%, about 20% to about 80%, about 20% to about 20%, about 20% to about 60%, about 20% to about 50%, about 20% to about 40%, about 30% to about 100%, about 30% to about 90%, about 30% to about 80%, about 30% to about 70%, about 30% to about 60%, or about 30% to about 50%. 
     In yet other aspects of this embodiment, a therapeutically effective amount of IVIG with or without a cortical steroid as disclosed herein generally is in the range of about 0.001 g/kg/day to about 10 g/kg/day. In aspects of this embodiment, an effective amount of IVIG with or without a cortical steroid as disclosed herein may be, e.g., at least 0.01 g/kg/day, at least 0.05 g/kg/day, at least 0.1 g/kg/day, at least 0.2 g/kg/day, at least 0.3 g/kg/day, at least 0.4 g/kg/day, at least 0.5 g/kg/day, at least 0.6 g/kg/day, at least 0.7 g/kg/day, at least 0.8 g/kg/day, at least 0.9 g/kg/day, at least 1 g/kg/day, at least 1.1 g/kg/day, at least 1.2 g/kg/day, at least 1.3 g/kg/day, at least 1.4 g/kg/day, at least 1.5 g/kg/day, at least 1.6 g/kg/day, at least 1.7 g/kg/day, at least 1.8 g/kg/day, at least 1.9 g/kg/day, at least 2g/kg/day, at least 2.1 g/kg/day, at least 2.2 g/kg/day, at least 2.3 g/kg/day, at least 2.4 g/kg/day, at least 2.5 g/kg/day, at least 2.6 g/kg/day, at least 2.7 g/kg/day, at least 2.8 g/kg/day, at least 2.9 g/kg/day, at least 3 g/kg/day, at least 3.1 g/kg/day, at least 3.2 g/kg/day, at least 3.3 g/kg/day, at least 3.4 g/kg/day, at least 3.5 g/kg/day, at least 3.6 g/kg/day, at least 3.7 g/kg/day, at least 3.8 g/kg/day, at least 3.9 g/kg/day, at least 4 g/kg/day, at least 4.1 g/kg/day, at least 4.2 g/kg/day, at least 4.3 g/kg/day, at least 4.4 g/kg/day, at least 4.5 g/kg/day, at least 4.6 g/kg/day, at least 4.7 g/kg/day, at least 4.8 g/kg/day, at least 4.9 g/kg/day, at least 5 g/kg/day, at least 6 g/kg/day, at least 7 g/kg/day, at least 8 g/kg/day, at least 9 g/kg/day, or at least 10 g/kg/day. In other aspects of this embodiment, an effective amount of IVIG with or without a cortical steroid as disclosed herein may be in the range of, e.g., about 1 g/kg/day to about 10 g/kg/day, about 1 g/kg/day to about 7.5 g/kg/day, about 1 g/kg/day to about 6 g/kg/day, about 1 g/kg/day to about 5 g/kg/day, about 2 g/kg/day to about 10 g/kg/day, about 2 g/kg/day to about 7.5 g/kg/day, about 2 g/kg/day to about 6 g/kg/day, about 2 g/kg/day to about 5 g/kg/day, about 3 g/kg/day to about 10 g/kg/day, about 3 g/kg/day to about 7.5 g/kg/day, or about 3 g/kg/day to about 6 g/kg/day. In yet other aspects of this embodiment, an effective amount of IVIG with or without a cortical steroid as disclosed herein may be in the range of, e.g., about 1 g/kg/day to about 10 g/kg/day, about 1 g/kg/day to about 7.5 g/kg/day, about 1 g/kg/day to about 6 g/kg/day, about 1 g/kg/day to about 5 g/kg/day, about 2 g/kg/day to about 10 g/kg/day, about 2 g/kg/day to about 7.5 g/kg/day, about 2 g/kg/day to about 6 g/kg/day, about 2 g/kg/day to about 5 g/kg/day, about 3 g/kg/day to about 10 g/kg/day, about 3 g/kg/day to about 7.5 g/kg/day, or about 3 g/kg/day to about 6 g/kg/day. In still other aspects of this embodiment, an effective amount of IVIG with or without a cortical steroid as disclosed herein may be in the range of, about 1 g/kg/day to about 10 g/kg/day, about 1 g/kg/day to about 7.5 g/kg/day, about 1 g/kg/day to about 6 g/kg/day, about 1 g/kg/day to about 5 g/kg/day, about 2 g/kg/day to about 10 g/kg/day, about 2 g/kg/day to about 7.5 g/kg/day, about 2 g/kg/day to about 6 g/kg/day, about 2 g/kg/day to about 5 g/kg/day, about 3 g/kg/day to about 10 g/kg/day, about 3 g/kg/day to about 7.5 g/kg/day, or about 3 g/kg/day to about 6 g/kg/day. 
     In other aspects of this embodiment, an effective amount of IVIG with or without a cortical steroid as disclosed herein may be in the range of, e.g., about 1 g/kg/day to about 10 g/kg/day, about 1 g/kg/day to about 7.5 g/kg/day, about 1 g/kg/day to about 6 g/kg/day, about 1 g/kg/day to about 5 g/kg/day, about 2 g/kg/day to about 10 g/kg/day, about 2 g/kg/day to about 7.5 g/kg/day, about 2 g/kg/day to about 6 g/kg/day, about 2 g/kg/day to about 5 g/kg/day, about 3 g/kg/day to about 10 g/kg/day, about 3 g/kg/day to about 7.5 g/kg/day, or about 3 g/kg/day to about 6 g/kg/day. In yet other aspects of this embodiment, an effective amount of IVIG with or without a cortical steroid as disclosed herein may be in the range of, e.g., about 1 g/kg/day to about 10 g/kg/day, about 1 g/kg/day to about 7.5 g/kg/day, about 1 g/kg/day to about 6 g/kg/day, about 1 g/kg/day to about 5 g/kg/day, about 2 g/kg/day to about 10 g/kg/day, about 2 g/kg/day to about 7.5 g/kg/day, about 2 g/kg/day to about 6 g/kg/day, about 2 g/kg/day to about 5 g/kg/day, about 3 g/kg/day to about 10 g/kg/day, about 3 g/kg/day to about 7.5 g/kg/day, or about 3 g/kg/day to about 6 g/kg/day. 
     In liquid, semi-solid and solid formulations, a concentration of a Hearing Loss, including Sudden Sensorineural Healing Loss therapeutic disclosed herein typically may be between about 0.001 g/mL to about 10 g/mL, about 0.001 g/mL to about 10 mg/mL, about 0.001 g/mL to about 5 mg/mL, about 0.5 g/mL to about 10 mg/mL, about 0.01 g/mL to about 10 g/mL, about 0.005 g/mL to about 10 mg/mL, about 0.005 g/mL to about 5 mg/mL, about 0.001 g/mL to about 6 g/mL, about 0.1 mg/mL to about 10 g/mL, about 0.1 g/mL to about 5 g/mL, about 0.5 g/mL to about 5 g/mL, about 1 g/mL to about 10 g/mL, about 2.5 g/mL to about 6 g/mL, about 3 g/mL to about 6 g/mL, about 4 g/mL to about 6 g/mL, about 1 g/mL to about 5 g/mL, about 1 g/mL to about 6 g/mL, about 2.5 g/mL to about 5 g/mL, about 3.5 g/mL to about 5 g/mL, about 4 g/mL to about 5 g/mL, about 3 g/mL to about 5 g/mL. 
     Dosing can be single dosage or cumulative (serial dosing), and can be readily determined by one skilled in the art. A Hearing Loss, including Sudden Sensorineural Healing Loss therapeutic may be administered once, twice, three, four, five, six, seven, eight, nine, ten, eleven, twelve, thirteen, fourteen, fifteen, sixteen, seventeen, eighteen, nineteen, twenty or more times to a subject. For instance, treatment of Hearing Loss, including Sudden Sensorineural Healing Loss may comprise a one-time administration of an effective dose of IVIG with or without a cortical steroid as disclosed herein. Alternatively, treatment of Hearing Loss, including Sudden Sensorineural Healing Loss may comprise multiple administrations of an effective dose of IVIG with or without a cortical steroid as carried out over a range of time periods, such as, e.g., once daily, twice daily, trice daily, once every few days, or once weekly. The timing of administration can vary from individual to individual, depending upon such factors as the severity of an individual&#39;s symptoms. For example, an effective dose of IVIG with or without a cortical steroid as disclosed herein can be administered to an individual once daily for an indefinite period of time, or until the individual no longer requires therapy. A person of ordinary skill in the art will recognize that the condition of the individual can be monitored throughout the course of treatment and that the effective amount of a pharmaceutical composition disclosed herein that is administered can be adjusted accordingly. 
     In one embodiment, IVIG with or without a cortical steroid as disclosed herein is capable of decreasing the time to resolve the symptoms of Hearing Loss, including Sudden Sensorineural Healing Loss in an individual suffering from a Hearing Loss by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90% or at least 95% as compared to a patient not receiving the same treatment. In other aspects of this embodiment, IVIG with or without a cortical steroid as disclosed is capable of decreasing the time to resolve the symptoms of Hearing Loss, including Sudden Sensorineural Healing Loss in an individual suffering from a Hearing Loss, including Sudden Sensorineural Healing Loss by, e.g., about 10% to about 100%, about 20% to about 100%, about 30% to about 100%, about 40% to about 100%, about 50% to about 100%, about 60% to about 100%, about 70% to about 100%, about 80% to about 100%, about 10% to about 90%, about 20% to about 90%, about 30% to about 90%, about 40% to about 90%, about 50% to about 90%, about 60% to about 90%, about 70% to about 90%, about 10% to about 80%, about 20% to about 80%, about 30% to about 80%, about 40% to about 80%, about 50% to about 80%, or about 60% to about 80%, about 10% to about 70%, about 20% to about 70%, about 30% to about 70%, about 40% to about 70%, or about 50% to about 70% as compared to a patient not receiving the same treatment. 
     In a further embodiment, IVIG with or without a cortical steroid and its derivatives have half-lives of 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 1 week, 2 weeks, 3 weeks, 4 weeks, one month, two months, three months, four months or more. 
     In an embodiment, the period of administration of a Hearing Loss therapeutic is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. In a further embodiment, a period of during which administration is stopped is for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days, 11 days, 12 days, 13 days, 14 days, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, 12 months, or more. 
     In aspects of this embodiment, a therapeutically effective amount of IVIG with or without a cortical steroid as disclosed is capable of decreasing the time to resolve the symptoms of Hearing Loss, including Sudden Sensorineural Healing Loss in an individual suffering from a Hearing Loss by, e.g., at least 10%, at least 15%, at least 20%, at least 25%, at least 30%, at least 35%, at least 40%, at least 45%, at least 50%, at least 55%, at least 60%, at least 65%, at least 70%, at least 75%, at least 80%, at least 85%, at least 90%, at least 95% or at least 100% as compared to a patient not receiving the same treatment. 
     IVIG with or without a cortical steroid or a Hearing Loss, including Sudden Sensorineural Healing Loss therapeutic is administered to an individual. An individual is typically a human being, but can be an animal, including, but not limited to, dogs, cats, birds, cattle, horses, sheep, goats, reptiles and other animals, whether domesticated or not. Typically, any individual who is a candidate for treatment is a candidate with Hearing Loss, including Sudden Sensorineural Healing Loss. 
     In an embodiment, in instances in which each of the Hearing Loss, including Sudden Sensorineural Healing Loss therapeutics themselves are administered, without limitation, as individual or separate dosage forms (e.g., capsules, tablets or liquid), the kit comprises, without limitation, each of the Hearing Loss, including Sudden Sensorineural Healing Loss therapeutics making up the composition of the invention, along with instructions for use. In an additional embodiment, the Hearing Loss, including Sudden Sensorineural Healing Loss therapeutic components, without limitation, may be packaged in any manner suitable for administration, so long as the packaging, when considered along with the instructions for administration, without limitation, clearly indicates the manner in which each of the Hearing Loss, including Sudden Sensorineural Healing Loss therapeutic components is to be administered. In a further embodiment, each of the Hearing Loss, including Sudden Sensorineural Healing Loss therapeutics or a combination of such Hearing Loss, including Sudden Sensorineural Healing Loss therapeutics may, without limitation, be combined into a single administrable dosage form such as a liquid, including a liquid administered subcutaneously or other liquid formulation. The Hearing Loss, including Sudden Sensorineural Healing Loss therapeutic can be provided to an individual in a package. The package can be a container, for instance, without limitation, a bottle, a canister, a tube or other enclosed vessel. In an embodiment, the Hearing Loss therapeutic is IVIG with or without a steroid, including, a cortical steroid, including prednisone. 
     EXAMPLES 
     The following non-limiting examples are provided for illustrative purposes only in order to facilitate a more complete understanding of representative embodiments now contemplated. These examples are intended to be a mere subset of all possible contexts in which the method for treating Sudden Sensorineural Hearing Loss may be utilized. Thus, these examples should not be construed to limit any of the embodiments described in the present specification, including those pertaining to administering a therapeutically effective amount of a composition comprising human intravenous immunoglobulin (IVIG) to a subject and a steroid. Ultimately, the method for administering a therapeutically effective amount of a composition comprising human intravenous immunoglobulin (IVIG) to a subject and a steroid may be utilized in virtually any context where treating Sudden Sensorineural Hearing Loss is desired. 
     Example 1 
     Treatment of 50-Year-Old Female Suffering from Hearing Loss 
     The patient, a 50-year-old female was diagnosed by her doctor after claiming she is suffering from unexplained hearing loss. The patient&#39;s doctor diagnosed the patient as suffering from Sudden Sensorineural Healing Loss. The patient is put on 60 mg/day prednisone therapy and showed no reduction in the symptoms she suffers. Two weeks after administration, the patient is co-administered a single dose of IVIG at 2 g/kg and 60 mg prednisone and Sudden Sensorineural Healing Loss related symptoms the patient suffered from. Following the treatment with IVIG, the patient had a complete recovery in her hearing. 
     Example 2 
     Treatment of a 48-Year-Old Male Suffering from Hearing Loss 
     The patient, a 48-year-old male is diagnosed by his doctor as suffering from Sudden Sensorineural Hearing Loss. The patient is put on 60 mg/day prednisone therapy for a period of a month and the Sudden Sensorineural Hearing Loss did not resolve. The patient is then administered IVIG at 2 g/kg and 60 mg prednisone. Within three weeks, the Sudden Sensorineural Hearing Loss is resolved by about 80%. The patient is then administered a second dose of IVIG at 2 g/kg and 60 mg. prednisone. Within two weeks, the patient is resolved by about 95%. A week later, the patient&#39;s Sudden Sensorineural Hearing Loss symptoms have disappeared and the patient presents as normal. 
     Certain embodiments of the present invention are described herein, including the best mode known to the inventor(s) for carrying out the invention. Of course, variations on these described embodiments will become apparent to those of ordinary skill in the art upon reading the foregoing description. The inventor(s) expect skilled artisans to employ such variations as appropriate, and the inventor(s) intend for the present invention to be practiced otherwise than specifically described herein. Accordingly, this invention includes all modifications and equivalents of the subject matter recited in the claims appended hereto as permitted by applicable law. Moreover, any combination of the above-described embodiments in all possible variations thereof is encompassed by the invention unless otherwise indicated herein or otherwise clearly contradicted by context. 
     Groupings of alternative embodiments, elements, or steps of the present invention are not to be construed as limitations. Each group member may be referred to and claimed individually or in any combination with other group members disclosed herein. It is anticipated that one or more members of a group may be included in, or deleted from, a group for reasons of convenience and/or patentability. When any such inclusion or deletion occurs, the specification is deemed to contain the group as modified thus fulfilling the written description of all Markush groups used in the appended claims. 
     Unless otherwise indicated, all numbers expressing a characteristic, item, quantity, parameter, property, term, and so forth used in the present specification and claims are to be understood as being modified in all instances by the term “about.” As used herein, the term “about” means that the characteristic, item, quantity, parameter, property, or term so qualified encompasses a range of plus or minus ten percent above and below the value of the stated characteristic, item, quantity, parameter, property, or term. Accordingly, unless indicated to the contrary, the numerical parameters set forth in the specification and attached claims are approximations that may vary. At the very least, and not as an attempt to limit the application of the doctrine of equivalents to the scope of the claims, each numerical indication should at least be construed in light of the number of reported significant digits and by applying ordinary rounding techniques. Notwithstanding that the numerical ranges and values setting forth the broad scope of the invention are approximations, the numerical ranges and values set forth in the specific examples are reported as precisely as possible. Any numerical range or value, however, inherently contains certain errors necessarily resulting from the standard deviation found in their respective testing measurements. Recitation of numerical ranges of values herein is merely intended to serve as a shorthand method of referring individually to each separate numerical value falling within the range. Unless otherwise indicated herein, each individual value of a numerical range is incorporated into the present specification as if it were individually recited herein. Similarly, as used herein, unless indicated to the contrary, the term “substantially” is a term of degree intended to indicate an approximation of the characteristic, item, quantity, parameter, property, or term so qualified, encompassing a range that can be understood and construed by those of ordinary skill in the art. 
     Use of the terms “may” or “can” in reference to an embodiment or aspect of an embodiment also carries with it the alternative meaning of “may not” or “cannot.” As such, if the present specification discloses that an embodiment or an aspect of an embodiment may be or can be included as part of the inventive subject matter, then the negative limitation or exclusionary proviso is also explicitly meant, meaning that an embodiment or an aspect of an embodiment may not be or cannot be included as part of the inventive subject matter. In a similar manner, use of the term “optionally” in reference to an embodiment or aspect of an embodiment means that such embodiment or aspect of the embodiment may be included as part of the inventive subject matter or may not be included as part of the inventive subject matter. Whether such a negative limitation or exclusionary proviso applies will be based on whether the negative limitation or exclusionary proviso is recited in the claimed subject matter. 
     The terms “a,” “an,” “the” and similar references used in the context of describing the present invention (especially in the context of the following claims) are to be construed to cover both the singular and the plural, unless otherwise indicated herein or clearly contradicted by context. Further, ordinal indicators—such as “first,” “second,” “third,” etc.—for identified elements are used to distinguish between the elements, and do not indicate or imply a required or limited number of such elements, and do not indicate a particular position or order of such elements unless otherwise specifically stated. All methods described herein can be performed in any suitable order unless otherwise indicated herein or otherwise clearly contradicted by context. The use of any and all examples, or exemplary language (e.g., “such as”) provided herein is intended merely to better illuminate the present invention and does not pose a limitation on the scope of the invention otherwise claimed. No language in the present specification should be construed as indicating any non-claimed element essential to the practice of the invention. 
     When used in the claims, whether as filed or added per amendment, the open-ended transitional term “comprising” (along with equivalent open-ended transitional phrases thereof such as “including,” “containing” and “having”) encompasses all the expressly recited elements, limitations, steps and/or features alone or in combination with un-recited subject matter; the named elements, limitations and/or features are essential, but other unnamed elements, limitations and/or features may be added and still form a construct within the scope of the claim. Specific embodiments disclosed herein may be further limited in the claims using the closed-ended transitional phrases “consisting of” or “consisting essentially of” in lieu of or as an amendment for “comprising.” When used in the claims, whether as filed or added per amendment, the closed-ended transitional phrase “consisting of” excludes any element, limitation, step, or feature not expressly recited in the claims. The closed-ended transitional phrase “consisting essentially of” limits the scope of a claim to the expressly recited elements, limitations, steps and/or features and any other elements, limitations, steps and/or features that do not materially affect the basic and novel characteristic(s) of the claimed subject matter. Thus, the meaning of the open-ended transitional phrase “comprising” is being defined as encompassing all the specifically recited elements, limitations, steps and/or features as well as any optional, additional unspecified ones. The meaning of the closed-ended transitional phrase “consisting of” is being defined as only including those elements, limitations, steps and/or features specifically recited in the claim, whereas the meaning of the closed-ended transitional phrase “consisting essentially of” is being defined as only including those elements, limitations, steps and/or features specifically recited in the claim and those elements, limitations, steps and/or features that do not materially affect the basic and novel characteristic(s) of the claimed subject matter. Therefore, the open-ended transitional phrase “comprising” (along with equivalent open-ended transitional phrases thereof) includes within its meaning, as a limiting case, claimed subject matter specified by the closed-ended transitional phrases “consisting of” or “consisting essentially of.” As such, embodiments described herein or so claimed with the phrase “comprising” are expressly or inherently unambiguously described, enabled and supported herein for the phrases “consisting essentially of” and “consisting of.” 
     All patents, patent publications, and other publications referenced and identified in the present specification are individually and expressly incorporated herein by reference in their entirety for the purpose of describing and disclosing, for example, the compositions and methodologies described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by virtue of prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents is based on the information available to the applicants and does not constitute any admission as to the correctness of the dates or contents of these documents. 
     While aspects of the invention have been described with reference to at least one exemplary embodiment, it is to be clearly understood by those skilled in the art that the invention is not limited thereto. Rather, the scope of the invention is to be interpreted only in conjunction with the appended claims and it is made clear, here, that the inventor(s) believe that the claimed subject matter is the invention.